Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing

用于原位检测和功能测量基因组编辑引起的不良后果的人体微组织

• 批准号: 10455604
• 负责人: Bruce R Conklin
• 金额: $ 72.08万
• 依托单位: J. DAVID GLADSTONE INSTITUTES
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-25 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10455604
• 关键词: 3-Dimensional; Adverse effects; Adverse event; Affect; Alleles; Animal Model; Biological; Biological Assay; Biological Markers; Cardiac; Cardiac Myocytes; Cell Death; Cell Differentiation process; Cells; Clinical; Clinical Medicine; Congenital Disorders; DNA Sequence Alteration; Detection; Development; Disease; Disease model; Dominant-Negative Mutation; Effectiveness; Engineering; Event; Excision; Exhibits; Exposure to; Failure; Future; Genes; Genetic Diseases; Genome; Genomic DNA; Genomics; Goals; Heart; Hepatobiliary; Hepatotoxicity; Human; Human Development; Human Engineering; In Situ; Individual; Lead; Liver; Liver diseases; Measurement; Measures; Mechanics; Metabolic; Methods; Mitotic; Modern Medicine; Mutate; Natural regeneration; Nervous system structure; Neurons; Organ; Organ failure; Organoids; Outcome; Patients; Pharmaceutical Preparations; Physiological; Pluripotent Stem Cells; Population; Reagent; Reporter; Research; Research Personnel; Safety; Site; Source; Specimen; System; Technology; Testing; Therapeutic Intervention; Tissue Engineering; Tissue Model; Tissues; Toxic effect; Transgenic Organisms; Translating; Work; adverse outcome; base editing; curative treatments; delivery vehicle; drug development; gene therapy; genome editing; human tissue; infancy; loss of function; mortality; multidisciplinary; neurotoxicity; novel; novel therapeutics; off-target site; postnatal; pre-clinical; relating to nervous system; response; somatic cell gene editing; stem cell biology; stem cell derived tissues; targeted nucleases; technology development; therapeutic gene; therapeutic genome editing; therapy development

PROJECT SUMMARY Genome editing technologies are advancing rapidly toward clinical therapies, but robust methods for accurately assessing the potential adverse effects of genome editing activity and delivery vehicles on physiological tissue function have yet to be developed and broadly disseminated. Since animal models are often poor predictors of human biological responses, it is imperative to establish well-defined tissue systems composed of human cells as an intermediate testbed to assess the safety as well as the efficacy of genome editing and its effect(s) on tissue function. Human pluripotent and post-natal tissue-derived stem cells provide valuable sources of human differentiated cells, such as cardiomyocytes, neurons and hepatobiliary cells, that can be used to create 3D tissues to model diseases and test therapies ex vivo. Traditionally, the toxicity of novel therapies in the heart, nervous system and liver manifest with severe consequences that can often lead to organ failure and mortality. For this reason, a thorough preclinical characterization of potential toxicities and adverse events caused by genome editing in human microtissues that recapitulate critical physiologic functions will be essential for these therapies to be ultimately translated for clinical use. The primary objective of this proposal is to develop and validate human tissue platforms capable of sensitively and accurately detecting adverse effects of genome editing on physiologic tissue function. To achieve this objective, we have established a multi-disciplinary team of leading investigators with complementary expertise in tissue engineering, genome editing, stem cell biology, single cell genomics and technology development. We will pursue this overall goal through three projects in parallel that focus initially on the development of individual microtissue platforms in concert with a specific genome editing strategy before proceeding to testing each of the editing scenarios on all three of the tissue systems. In the first project, we will examine the effects of single-site editing on defined off-target sites and endogenous loci on cardiac microtissue electrical and mechanical function. In the second project, we will examine large scale genomic alterations following deletion of variable size fragments in neurons and the effects on physiologic parameters. In the third project, we will assess biomarker expression and secretion by hepatobiliary microtissues following the genomic insertion of exogenous genes. These human tissue models tested with various clinical genome editing strategies will be integrated within the Somatic Gene Editing Consortium, to test novel delivery vehicles and help inform the development of future genome editing therapies. Altogether, the outcomes of this work should significantly benefit the safety and predictability of curative genome therapies of the future.

项目摘要 基因组编辑技术正在朝着临床治疗的方向迅速发展，但准确地 评估基因组编辑活动和递送载体对生理组织的潜在不利影响 功能尚待开发和广泛传播。由于动物模型通常不能很好地预测 人类的生物反应，必须建立由人类细胞组成的明确的组织系统 作为中间试验平台，评估基因组编辑的安全性和有效性及其对 组织功能人多能干细胞和出生后组织来源的干细胞提供了有价值的人造血干细胞来源。 分化的细胞，如心肌细胞，神经元和肝胆细胞，可用于创建3D 组织来模拟疾病和测试离体疗法。传统上，新疗法对心脏的毒性， 神经系统和肝脏表现出严重的后果，通常会导致器官衰竭和死亡。 出于这个原因，彻底的临床前表征的潜在毒性和不良事件引起的 在人类微组织中进行基因组编辑，重现关键的生理功能，对于这些研究至关重要。 最终转化为临床应用。本提案的主要目标是发展和 验证能够灵敏、准确检测基因组不良反应的人体组织平台 编辑生理组织功能。为达致这个目标，我们成立了一个跨专业的队伍， 领先的研究人员在组织工程，基因组编辑，干细胞生物学， 单细胞基因组学和技术开发。我们将通过以下三个项目来实现这一总体目标： 平行，最初专注于发展个别微组织平台与特定的 在对所有三种组织进行每种编辑方案测试之前， 系统.在第一个项目中，我们将检查单站点编辑对定义的非目标站点的影响， 内源性位点对心脏微组织电和机械功能的影响。在第二个项目中，我们将 检查神经元中删除可变大小片段后的大规模基因组改变及其影响 生理参数。在第三个项目中，我们将评估生物标志物的表达和分泌， 在外源基因的基因组插入后，肝胆微组织中。这些人体组织模型 使用各种临床基因组编辑策略进行测试将整合到体细胞基因编辑中。 联盟，以测试新型运载工具，并帮助为未来基因组编辑疗法的发展提供信息。 总之，这项工作的结果将大大有利于治疗性基因组的安全性和可预测性 未来的治疗。